soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm The impact of on events in patients with type 2 diabetes: review of from the Oral Semaglutide and Cardiovascular Outcomes

Cholecystitis was reported by 0.6% of Wegovy patients and 0.2% of placebo patients

Both weight loss medications work by mimicking natural hormones that regulate appetite and insulin levels

[1] Additionally, GLP-1 receptor agonists including semaglutide are associated with an increased risk of gallbladder disease, which can present with right upper quadrant pain, fever, or jaundice

Do not take activated charcoal within 2 hours of any medication, including your GLP-1 injection, as it can reduce medication absorption

Some coffee preparations may be gentler on the stomach than others, such as cold brew, which some find less acidic

Doses are per week, not per day